Page 552 - ஒளி வண்ண மலர்கள் கொண்ட ஒரு செடி வகை பெட்ரோலியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(3) New York, New York (Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company s plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL). Here are some key takeaways from the commercialization Q&A: 1. Soligenix will commercialize SGX301 in the U.S. on its own During the presentation, the company noted that after conducting necessary due diligence and simulating different routes to commercialization, it was determined that a partnership would not be the best solution for shareholders. The licensing landscape and CTCL s small, orphan market were the key drivers behind the decision. Considering that the average biopharmaceutical licensing deal, a Phase 3 licensor will typically retain no more than 40% of the produc

New yorkUnited statesChris schaberJonathan guarinoZack research updates soligenixYork newsfile corpCap researchAdvisory incDigital holdingsMultiple near term catalysts anticipatedNew drug applicationClinical study reportPrescription drug user fee actAmerican academyDermatology meetingInvestigative dermatology meeting